Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.
Am J Hematol. 2021 Jun 1;96(6):735-746. doi: 10.1002/ajh.26142. Epub 2021 Mar 18.
Differentiation Syndrome (DS) has been identified in a subset of patients undergoing treatment with novel classes of differentiating therapies for acute myeloid leukemia (AML) such as IDH and FLT3 inhibitors. While DS is a well-known treatment-related complication in acute promyelocytic leukemia (APL), efforts are still ongoing to standardize diagnostic and treatment parameters for DS in AML. Though the rates of incidence vary, many of the signs and symptoms of DS are common between APL and AML. So, DS can lead to fatal complications in AML, but prompt management is usually effective and rarely necessitates interruption or discontinuation of AML therapy.
分化综合征 (DS) 已在接受新型分化治疗急性髓系白血病 (AML) 的患者亚组中被识别，例如 IDH 和 FLT3 抑制剂。虽然 DS 是急性早幼粒细胞白血病 (APL) 中一种已知的治疗相关并发症，但仍在努力为 AML 中的 DS 标准化诊断和治疗参数。尽管发生率有所不同，但许多 DS 的体征和症状在 APL 和 AML 之间是常见的。因此，DS 可导致 AML 致命并发症，但及时治疗通常是有效的，很少需要中断或停止 AML 治疗。
